Lansoprazole outruns Ranitidine in the long term battle of GERD treatment

Home » Blog » Bulk Active Ingredient » Lansoprazole outruns Ranitidine in the long term battle of GERD treatment

Lansoprazole outruns Ranitidine in the long term battle of GERD treatment

gastroesophageal reflux diseaseIn developed nations, between 20-40 percent of adults experience heartburn on a regular basis. Heartburn is characterized by a burning sensation that rises from the stomach towards the chest and neck. It has often been mistaken as angina, a symptom of heart attack. Heartburn is the primary symptom of gastroesophageal reflux disease (GERD). When left untreated for a long time, it results in the inflammation and swelling up of the esophagus, a condition called erosive esophagitis. It is estimated that over half of GERD sufferers may have erosive esophagitis.

A multicenter study conducted by the CURE Digestive Diseases Research Center and the VA Greater Los Angeles Healthcare System, found that lansoprazole provides better quality of life for long time sufferers of GERD and its associated complication, erosive esophagitis.  The study used subjects with erosive esophagitis in order to evaluate its recurrence in those who were put in long term therapy with ranitidine and lansoprazole. The subjects were put into group 1 and group 2 with each group receiving a 12 month therapy with lansoprazole and ranitidine respectively.

The results of the study showed a significant difference between the two treatment groups, specifically favoring the lansoprazole treated subjects when reduced frequency, severity and inconvenience were tested. The decreased incidence of symptom outbreaks, severity and physical difficulties are indicators that point to improved quality of life. This is why the researchers concluded that putting patients with healed erosive esophagitis on maintenance therapy with lansoprazole for 12 months led to a more improved quality of life than those put on ranitidine therapy.

Relatively new drugs (such as the proton pump inhibitor Lansoprazole CAS# 103577-45-3) have a greater treatment role in certain disorders and diseases than what they were initially approved for. In light of these developments, LGM Pharma has not only kept its focus on the market for new studies, but it has also been a consistent supplier of Lansoprazole CAS# 103577-45-3 and Ranitidine Hydrochloride CAS# 71130-06-8. By lending their hand as a responsive supplier, the company believes that it has helped to invigorate similar research efforts by pharmaceutical organizations worldwide.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:
This website uses cookies. By using our site, you agree to our terms of service